The biotechnology industry had a rough first quarter after a decent performance in 2023. The majority of biotech players do not generate enough revenues to fund their operations and are dependent on external funds. A company starts generating revenues following a successful FDA approval and the launch of a drug.  Under this circumstance, a high interest rate regime is detrimental to the biotech industry. The primary reason for the industry’s weak performance year to date is that the Fed refrained from reduc ...

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Arcutis Biotherapeutics, Inc. (ARQT) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.Arcutis Biotherapeutics, Inc. is one of 1043 individual stocks in the Medical sector. Collectively, these companies sit at #7 in the Zacks Sector Rank. The Za ...

Shares of Arcutis Biotherapeutics, Inc. (ARQT) have gained 2.4% over the past four weeks to close the last trading session at $9.34, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $18.67 indicates a potential upside of 99.9%.The mean estimate comprises six short-term price targets with a standard deviation of $4.80. While the lowest estimate of $11 indicates a 17.8% increase fr ...

Investigational roflumilast cream 0.15% showed continued improvements in the signs and symptoms of AD, including itch, through 56 weeks of treatment 66.2% of participants treated with once-daily roflumilast cream 0.15% in both the 4-week parent study and the 52-week open label extension achieved a 75% improvement in Eczema Area and Severity Index (EASI-75) at Week 56 For participants who achieved disease clearance and switched to proactive twice weekly application of roflumilast cream, the median duration o ...

Investigational roflumilast cream 0.15% showed continued improvements in the signs and symptoms of AD, including itch, through 56 weeks of treatment66.2% of participants treated with once-daily roflumilast cream 0.15% in both the 4-week parent study and the 52-week open label extension achieved a 75% improvement in Eczema Area and Severity Index (EASI-75) at Week 56For participants who achieved disease clearance and switched to proactive twice weekly application of roflumilast cream, the median duration of ...

WESTLAKE VILLAGE, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 57,500 restricted stock units of Arcutis' common stock to six newly hired employees. These awards were approved by the Compensation Committee of Arcutis' Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, wit ...

Arcutis Biotherapeutics, Inc. (ARQT) closed the last trading session at $9.20, gaining 1.1% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $18.50 indicates a 101.1% upside potential.The mean estimate comprises six short-term price targets with a standard deviation of $4.81. While the lowest estimate of $11 indicates a 19.6% increase from the current price level, the most optimisti ...

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q1 2024 Earnings Conference Call May 14, 2024 4:30 PM ET Company Participants Latha Vairavan - Vice President, Finance and Head of Investor Relations Frank Watanabe - President and Chief Executive Officer Todd Edwards - Chief Commercial Officer Patrick Burnett - Chief Medical Officer David Topper - Chief Financial Officer Conference Call Participants Serge Belanger - Needham Seamus Fernandez - Guggenheim Securities Vikram Purohit - Morgan Stanley Tyler Van Buren - ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form10-Q 91361 (Zip Code) (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission File Number: 001-39186 ARCUTIS BIOTHERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or Other ...

Arcutis Announces First Quarter 2024 Financial Results and Provides Business Update • First quarter net product revenues for ZORYVE® franchise of $21.6M, with $15M for ZORYVE (roflumilast) cream 0.3%, and $6.5M for ZORYVE (roflumilast) topical foam, 0.3%; sales growth of 675% vs. Q1 '23 and 59% vs. Q4 '23 • Continued gross-to-net (GTN) improvement with blended GTN across products now in the low 60 percent range • Sustained growth in demand for cream and remarkable uptake of foam launched in January • July 7 ...